145 257

Cited 2 times in

Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma

 Keun Yeong Jeong  ;  Eun Jung Lee  ;  Seung Hyun Yang  ;  Jinsil Seong 
 JOURNAL OF RADIATION RESEARCH, Vol.56(1) : 37-45, 2015 
Journal Title
Issue Date
Animals ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage* ; Apoptosis/drug effects ; Apoptosis/radiation effects ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/therapy* ; Cell Line, Tumor ; Cell Survival/drug effects ; Cell Survival/radiation effects ; Chemokine CCL3/administration & dosage* ; Chemoradiotherapy/methods* ; Liver Neoplasms/pathology ; Liver Neoplasms/therapy* ; Male ; Mice ; Mice, Inbred C3H ; Niacinamide/administration & dosage ; Niacinamide/analogs & derivatives* ; Phenylurea Compounds/administration & dosage* ; Radiation Tolerance/drug effects ; Radiation-Sensitizing Agents/administration & dosage ; Treatment Outcome
MIP-1α ; hepatocellular carcinoma ; irradiation ; metastasis ; sorafenib
Existing therapies such as irradiation or sorafenib have limited success in the treatment of hepatocellular carcinoma (HCC) due to tumor recurrence and metastasis. Therefore, combination with other therapeutics is often considered. Macrophage inflammatory protein-1 alpha (MIP-1α) is a member of a family of chemoattractant cytokines that can induce the migration of monocytes, which in turn can play a role in fighting tumors. This study investigated whether intravenous injection of MIP-1α in conjunction with irradiation or sorafenib could enhance the antitumor effects on murine hepatoma. An HCa-I tumor was grown on the right thigh of each C3H/HeN mouse. Mice were then treated with 10 Gy of irradiation, sorafenib, or a combination of MIP-1α with either irradiation or sorafenib, and antitumor and antimetastatic effects were then investigated. To understand the mechanisms, changes in the level of immunological markers were also evaluated. Combination treatment of MIP-1α with irradiation or sorafenib resulted in a significant enhancement of antitumor effects, prevention of lung metastasis and increase in host survival. This was achieved by significantly increasing the levels of the immunological markers: Cluster Differentiation (CD) 8, CD107A and CD11C. We conclude that a combination treatment of MIP-1α with irradiation or sorafenib would be a useful strategy for management of hepatoma.
Files in This Item:
T201500171.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
Yang, Seung Hyun(양승현)
Lee, Eun Jung(이은정)
Jeong, Keun Yeong(정근영)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.